Trinity Biotech plc announced on August 20, 2025, that the in-country healthcare product regulatory authority granted key approval to initiate offshore and outsourced manufacturing of its World Health Organization (WHO) prequalified TrinScreen™ HIV rapid test. This approval enables Trinity Biotech to transition upstream production from its legacy in-house operations to a more cost-effective and scalable outsourced model. The company has now begun manufacturing under this new model.
This strategic shift is expected to unlock significant cost efficiencies, enhance scalability, and position the company for long-term financial health. It builds on the previously announced WHO approval for the offshored and outsourced upstream manufacturing activities of TrinScreen™ HIV. The transition to outsourced production reduces fixed costs and supports Trinity’s broader profitability and growth objectives.
CEO John Gillard stated that this key regulatory approval is a major step forward in the company's transformation journey. It allows the company to fully operationalize its offshore manufacturing model for TrinScreen™ HIV. This move is a critical milestone in the company’s transformation strategy, aimed at improving financial performance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.